(NASDAQ: TRAX) First Tracks Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.48%.
First Tracks Biotherapeutics's earnings in 2026 is N/A.On average, 13 Wall Street analysts forecast TRAX's earnings for 2026 to be -$148,415,203, with the lowest TRAX earnings forecast at -$157,222,855, and the highest TRAX earnings forecast at -$133,937,065. On average, 13 Wall Street analysts forecast TRAX's earnings for 2027 to be -$132,818,690, with the lowest TRAX earnings forecast at -$165,276,587, and the highest TRAX earnings forecast at -$107,674,895.
In 2028, TRAX is forecast to generate -$143,666,574 in earnings, with the lowest earnings forecast at -$189,087,621 and the highest earnings forecast at -$112,176,982.